FORM PTO 1449 (modified)				ATTY DOCKET NO.  APPLICATION NO.  DOI: 74.913						
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				1702.401600 09/674,913 APPLICANT						
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				GUSTAV GAUDERNACK, ET AL.						
Dated: February 8, 2001 Nat'l. Entry From: PCT/NO99/00141				FILIN	FILING DATE Novemb r 8, 2000			ROUP <b>647</b> <b>Unassigned</b>		
					U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		O L P NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
				\[ \text{\range r} \]		-				
				THE PARTY OF THE P	2001					
				( )	MADEMARKET					
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT		
CDV -		WO 98/45322	10/1998		WIPO			Υs		
(D)-		WO 97/12992	4/1997		WIPO			Υs		
(D)	1	WO 95/32731	12/1995		WIPO			Yes		
C3V -		WO 92/14756	9/1992		WIPO			Υs		
C37 -		WO 99/58552	11/1999		WIPO			Yes		
		ОТ	HER DOCUMENT	(S) (Includ	ling Author, Title, Date, Pertinent Pages, Etc.)					
C30 -		van Leeuwen et al., (1998, January), Science 279:242-247, "Frameshift Mutants of ß Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients"								
(20)		Vogel, (1998), Science 279:174, "Possible New Cause of Alzheimer's Disease Found"								
C20-		Gaudernack, (1996), Immunotechnology 2:3-9, "T cell responses against mutant <i>ras</i> : a basis for novel cancer vaccines"								
3		Gjertsen et al. (1996), Int. Jounal of Cancer 65:450-453, "Ex Vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study"								
6512		Gjertsen et al. (1997), Int. J. Cancer 72:784-790, "Cytotoxic CD4 <sup>+</sup> and CD8 <sup>+</sup> T-Lymphocytes, Generated by Mutant p21- <i>ras</i> (12Val) Peptide Vaccination of a Patient, Recognize Tumour Cells Carrying This Mutation"								
دي،		Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, "Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer"								
EXAMINER	0	Tellio ( &	<del></del>		DATE CONSIDERED 11/20/26	<b>x</b> 2				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet\_ 1\_ of \_ 2\_

JWB/NMD/llp

FORM PTO 1449 (modified)				ATTY	DOCKET NO. 1702.40	APPLICA	PLICATION NO. 09/674,913				
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)  Dated: February 8, 2001  Nat'l. Entry From: PCT/NO99/00141				GUSTAV GAUDERNACK, ET AL.							
				FILING DATE Nov mber 8, 2000				GROUP (GF)			
	U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	DATE NAME O 1 7 E				S SUBCLASS	FILING DATE IF APPROPRIATE		
						FEB 0 8 2001 55					
					PA	To.					
						RADEMARK					
			F	OREIGN I	PATENT DOCUMENT	rs					
		DOCUMENT NUMBER	DATE		COUNT	'RY	CLAS	S SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT		
		07	THER DOCUMENT(	(S) (Includi	ing Author, Title, Date	, Pertinent Pages, Etc.)					
C3N_		Terry et al., Alzheimer Disease, 1994, pp. 179-196, "Structural Basis of the Cognitiv Alterations in Alzheimer Disease".									
(D)-		Barinaga, Science, vol. 257, 1992, pp. 880-881, "Getting Some 'Backbone": How MHC Binds Peptides".									
TW-		Deres et al., Nature, vol. 342, 1989, pp. 561-564, " <i>In vivo</i> priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine".									
con-		Tighe et al., Immun. Today, vol. 19(2), 1998, pp. 89-97, "Gene vaccination: plasmid DNA is more than just a blueprint".									
EXAMINER		Mieles	3		DATE CONSIDERE	D 11/20/2					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2

JWB/NMD/llp